Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sagent Pharmaceuticals Inc Reaffirms FY 2013 Revenue Guidance; Raises FY 2013 Net Income Guidance


Monday, 6 May 2013 07:00am EDT 

Sagent Pharmaceuticals Inc announced that for fiscal 2013, it expects net revenue to be in the range of $220 million to $250 million. Based upon the above assumptions and first quarter performance, the Company has expanded its anticipated range for reported net income for fiscal 2013 to between $5 million and $15 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $238 million and net income of $2.4 million for fiscal 2013. 

Company Quote

26.55
0.17 +0.64%
22 Jul 2014